GlassScriptPhysician profile
Sharon M Ondreyco
NPI 1588688592
$1,975.24
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $202 · 2021: $44.60 · 2022: $26.01 · 2023: $512 · 2024: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.10 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $344.39 | 2019-2024 | |
| Janssen Biotech, INC. | $201.32 | 2019-2023 | Rybrevant |
| Merck Sharp & Dohme LLC | $197.53 | 2019-2023 | Keytruda, Lynparza |
| Eisai INC. | $156.38 | 2019-2023 | |
| Novo Nordisk INC | $142.99 | 2019 | |
| Amgen INC. | $142.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $79.61 | 2020-2024 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $67.22 | 2019-2023 | Reblozyl |
| Taiho Oncology, INC. | $52.75 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $47.47 | 2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $44.56 | 2019 | |
| Array Biopharma INC | $43.40 | 2023 | Mektovi, Lorbrena, Xalkori |
| Genzyme Corporation | $38.50 | 2023 | |
| Secura Bio, INC. | $36.06 | 2019 | |
| Genmab U.S., INC. | $32.99 | 2023 | Tivdak |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $32.08 | 2019 | |
| Cti Biopharma Corp. | $26.01 | 2022 | |
| Celgene Corporation | $23.84 | 2024 | Pomalyst |
| Progenics Pharmaceuticals, INC. | $20.11 | 2024 | |
| Tempus Ai, INC | $19.18 | 2024 | |
| Incyte Corporation | $18.16 | 2024 | Jakafi |
| Daiichi Sankyo INC. | $18.14 | 2020 | |
| Mirati Therapeutics, INC. | $18.05 | 2024 | Krazati |
| Stemline Therapeutics INC. | $17.60 | 2019 | |
| Blueprint Medicines Corporation | $17.26 | 2024 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $16.66 | 2019 | |
| Eusa Pharma (US) LLC | $16.34 | 2020 | |
| Springworks Therapeutics, INC. | $16.19 | 2024 | Ogsiveo |
| Exelixis INC. | $16.04 | 2019 | |
| Seagen INC. | $16.00 | 2023 | Padcev |
| Karyopharm Therapeutics INC. | $15.48 | 2023 | Xpovio |
| Puma Biotechnology, INC. | $15.02 | 2019 | |
| Rigel Pharmaceuticals, INC. | $13.26 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Ondreyco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.